Form 8-K - Current report:
SEC Accession No. 0000950170-24-106817
Filing Date
2024-09-16
Accepted
2024-09-16 16:05:40
Documents
12
Period of Report
2024-09-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tnya-20240912.htm   iXBRL 8-K 53315
2 EX-10.1 tnya-ex10_1.htm EX-10.1 439867
  Complete submission text file 0000950170-24-106817.txt   677177

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tnya-20240912.xsd EX-101.SCH 25872
14 EXTRACTED XBRL INSTANCE DOCUMENT tnya-20240912_htm.xml XML 4909
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40656 | Film No.: 241301073
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)